Back
Immunoassay Update
Over the last year, our primary focus has been on responding to the surge in demand for outsourcing of bioanalysis services. This has originated from both the Pharma industry and the Specialist Healthcare sector. We predicted a significant increase in demand over this period in our last update - if anything, its extent has exceeded our expectations. One of the drivers for this has been the recent drastic downsizing in R&D resource within big Pharma organisations; the need for extensive costcutting in the healthcare sector has also contributed. A significant proportion of the increase in demand for our immunoassay (IA) services over the past year has resulted from our involvement in novel companion diagnostics projects. This has resulted in a significant increase in IA workload at YBS.
“A significant proportion of the increase in demand for our immunoassay services over the past year has resulted from our involvement in novel companion diagnostics projects”
To read the full text of this article you need to be registered with us. If you have already done so you can Login Now, or alternatively please Register your details with us.
Back
Printer Friendly  |   Sitemap © Unilabs Bioanalytical Solutions 2010 - 2017  |   Privacy Policy  |   Website Disclaimer  |   Website Credits